Calidi Biotherapeutics Q3 net loss widens to $5.1M; FDA clears NeuroNova IND

Calidi Biotherapeutics, Inc.

2024-Q3 EPS reported -$3.54

Net loss of $5.1M ($0.65/share) vs. $2.0M ($1.41/share) in Q3 2023.
R&D expenses $2.2M, down from $3.3M; G&A $3.1M, down from $4.0M.
Cash and restricted cash $2.1M as of Sept 30, 2024, unchanged from Dec 31, 2023.
FDA cleared IND for NeuroNova (CLD-101) Phase 1b/2 trial in high-grade glioma; trial expected early 2025.
Raised $2M in registered direct offering and private placement in October.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.